ArticleBMC gastroenterology2025
Retrospective study: analysis of risk factors and construction of prediction model for pancreatic steatosis.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Establishment and Comparative Analysis of Four Mouse Models for the Study of Pancreatic Steatosis.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundPancreatic steatosis, closely related to various metabolic diseases has no unified standard for the diagnosis. The purpose of this study was to construct and validate a risk prediction model of pancreatic steatosis.
methods854 cases admitted to Xi'an Mei Zhao physical examination center were divided into modeling set (n = 598) and validation set (n = 256) according to the ratio of 7:3, and the risk prediction model was constructed and validated based on the risk factors.
resultsOf 598 cases in modeling set, 232 were in the pancreatic steatosis group and 366 were in the non pancreatic steatosis group. There were significantly statistical differences in Age, Gender, Body Mass Index (BMI), Glucose (GLU), Total Cholesterol (TC), Triglycerides (TG), High-Density Lipoprotein (HDL), Low-Density Lipoprotein (LDL), Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Ratio of Aspartate Aminotransferase to Alanine Aminotransferase (AST/ALT), Non-Alcoholic Fatty Liver Disease (NAFLD), Pancreas computed tomography (CT) value, Spleen CT value, Liver CT value as well as Pancreas/Spleen CT value (P < 0.05) between pancreatic steatosis cases and non pancreatic steatosis cases. Cox regression showed that Age (97.5% CI 0.981-1.030), BMI (97.5% CI 1.198-1.436), GLU (97.5% CI 0.921-1.521), TC (97.5% CI 0.800-2.130), HDL (97.5% CI 0.074-0.649), LDL (97.5% CI 0.603-1.877), AST/ALT (97.5% CI 0.241-0.917), Pancreas CT value (97.5% CI 0.788-0.904), Liver CT value (97.5% CI 0.962-1.015), and Pancreas/Spleen CT value (97.5% CI 0.001-0.649) were independent risk factors for pancreatic steatosis (P < 0.05). Based on above variables, a pancreatic steatosis model was successfully constructed, the validation results showed the model had good credibility and predictive value.
conclusionAge, BMI, GLU, TC, HDL, LDL, AST/ALT, Pancreas CT value, Liver CT value, Pancreas/Spleen CT value are risk factors for pancreatic steatosis, and this model can identify the patients at high risk of pancreatic steatosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.